Dublin, December 30, 2020 (GLOBE NEWSWIRE) – Added to the report “Viral Vector and Plasmid DNA Manufacturing Market – Growth, Trend, and Projections (2020 – 2025)” ResearchAndMarkets.com’s offering.
Viral vectors and plasmid DNA are the products of gene therapy, which is used to treat a large number of diseases. The benefits of gene vaccines and gene therapy over conventional vaccines and therapies include the ability to stimulate a wide range of types of immune response.
A number of players, including pharmaceutical companies, research institutes, contract manufacturing organizations, and nonprofits, play a critical role in the development and production of these vectors.
Several clinical studies have been conducted on viral vectors and plasmid DNA fabrication, which emphasize the ability of gene therapy to address important medical needs, and have initiated an increase in investments in drug development and commercialization of these therapies. .
Factors, such as technological advances to reduce challenges posed by conventional methods of vector production, an increase in the number of clinical studies, and a growing number of gene therapy candidates, are accompanied by their rapid progress through varying degrees of clinical development, significantly driving the demand for viral and plasmid DNA fabrication.
Key market trends
Plasmid DNA Segment is expected to record strong growth.
Plasmid DNA is a small DNA molecule inside a cell that is different from the chromosomal DNA, which is able to reproduce independently. Plasmid DNA is currently becoming increasingly important, as a result of the clinical research applications in gene therapy and genetic immunization.
The therapeutic demand and applications for plasmid DNA (pDNA) have grown and expanded rapidly. Plasmid DNA fabrication is used for both indirect and direct clinical applications. For the direct transfer of genes into the human body, good manufacturing practice (GMP) -grade plasmid DNA is required. Plasmid DNA production is always outsourced to specific manufacturers using in-house platform processes.
For example, in December 2019, Genopis, a manufacturer of DNA plasmid in San Diego, to launch GMP Contract Manufacturing Industry for plasmid DNA production. In addition, with the growing R&D of cancer research due to the growing burden, the growing demand for DNA therapy is expected to stimulate the growth of the piece. over the forecast period.
North America dominates the market in terms of revenue generated
Currently, the North American viral vector and plasmid manufacturing market is seeing rapid growth in the surveyed market, followed by Europe. The United States has been a major destination for all recent advances in the field of medicine. Increased investments in gene therapy products in the United States have led to the growth of the market observed in recent years.
In the United States, regulatory motivation and patient advocacy have pushed the clinical study of rare diseases to the forefront. The major incentives offered by the Orphan Drugs Act (United States) and the Orphan Medicines Products Regulations (European Union) have encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as an effort to could be profitable.
Competitive Landscape
The market studied is still at a child level. Thus, the growing focus is on the development of innovative products. Key market players include Brammer Bio, Cobra Biologics, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, MassBiologics, SIRION Biotech, Merck KGaA Inc, Thermo Fisher Scientific, and Uniqure NV, among others.
Key topics covered:
1 INTRODUCTION
1.1 Delivery Monitoring
1.2 Exploration of assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 SUMMARY
4 MARKET DYNAMICS
4.1 Market outlook
4.2 Market drivers
4.2.1 Extension of genetic disorders, cancers and infectious diseases
4.2.2 Increase in the number of Clinical Studies and the availability of funding for the development of gene therapy
4.2.3 Potential applications in modern drug delivery methods
4.3 Market barriers
4.3.1 High Cost of Gene Therapies
4.3.2 Challenges in the viability of viral viruses
4.4 Porter Force Five Review
5 MARKET VIEW
5.1 Depending on the type of product
5.1.1 Plasmid DNA
5.1.2 Vector viral
5.1.3 Non-viral vector
5.2 By Request
5.2.1 cancer
5.2.2 Genetic disorder
5.2.3 Infectious disease
5.2.4 Other diseases
5.3 Geography
6 COMPETITIVE LAND
6.1 Company Profiles
6.1.1 Brammer Bio
6.1.2 Cobra Biology
6.1.3 Cell and Gene Therapy Catapult
6.1.4 FinVector vision treatments
6.1.5 Fujifilm Diosynth Biotechnologies
6.1.6 MassBiologics
6.1.7 SIRION Biotech
6.1.8 Merck KGaA Inc.
6.1.9 Thermo Fisher Science
6.1.10 NV without comparison
7 MARKET OPPORTUNITIES AND FUTURE RESULTS
For more information about this report, visit https://www.researchandmarkets.com/r/oxqhcq
Research and Markets also offers Custom Search services providing targeted, complete and unique search.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900